Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31626072 | 0.95 | CYP4F2 (0.37) | DUTCYP4F2CYP4A11 | |
| SCHEMBL17891871 | 0.83 | CYP4F2 (0.54) | DUTCYP4F2CYP4A11PPARA | |
| SCHEMBL15863148 | 0.82 | DUT (0.37) | DUTPPARA | |
| SCHEMBL769048 | 0.78 | DGAT1 (0.37) | BACE1 | |
| SCHEMBL30724478 | 0.78 | CYP4F2 (0.59) | DUTCYP4F2CYP4A11 | |
| SCHEMBL2139741 | 0.78 | CYP4F2 (0.59) | DUTCYP4F2CYP4A11 | |
| SCHEMBL13355267 | 0.77 | CYP4F2 (0.40) | CYP4F2CYP4A11PPARA | |
| SCHEMBL6258518 | 0.76 | CYP4F2 (0.39) | CYP4F2CYP4A11PPARA | |
| SCHEMBL31581201 | 0.76 | POLB (0.35) | DUT | |
| SCHEMBL11635954 | 0.75 | TSHR (0.50) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220503-A1 | Hydroxylation, carboxylation, cyclization, esterification, epoxidation, etherification | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-11-27 | — | — | US | disclosed |
| US-6605726-B1 | Method for producing epothilone B and derivatives, and intermediate products for this method | SCHERING AG (DE) | 2003-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220503-A1 | Hydroxylation, carboxylation, cyclization, esterification, epoxidation, etherification | CYP4A11, CYP4B1, CYP4F11 | DUT 2811/4885CYP4F2 13/4885CYP4A11 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.